Arcturus Therapeutics (ARCT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ARCT Arcturus Therapeutics

Watchlist

18.340
+0.830+4.74%

Close Nov 29 13:00 ET

18.340
0.0000.00%

Post 17:01 ET

496.78MMarket Cap-7871P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
BusinesswireNov 18 20:00 ET
Express News | Meiji Seika Pharma Announces Investment in Arcalis, Inc.
ReutersNov 14 01:00 ET
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
BusinesswireNov 14 01:00 ET
Arcturus Therapeutics: Overcoming Challenges and Poised for European Expansion
TipRanksNov 13 02:07 ET
We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate
Simply Wall StNov 12 09:08 ET
Arcturus Therapeutics Receives FDA Clearance to Begin H5N1 Vaccine Trial
TipRanksNov 11 16:05 ET

Comments

Laurence john tawil

May 28 10:16

$Arcturus Therapeutics (ARCT.US)$ wtf is happening bout to put this hoe down

Moomoo AI

Mar 9 06:57

Analysts maintain loss per share estimates for next year with no major changes to revenue estimates. However, the company's performance is expected to underperform the wider industry. The steady consensus price target indicates that reduced loss estimates may not positively impact the stock's long-term valuation.

Analysts Have Made A Financial Statement On Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Yearly Report

Moomoo AI

Feb 28 06:46

Despite Arcturus Therapeutics Holdings Inc.'s strong run, its P/S ratio remains low due to a weak revenue outlook. Investors believe the potential for revenue improvement doesn't justify a higher P/S ratio, forming a barrier for the share price.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Bigmoney Dreamer

Feb 9 12:29

$Arcturus Therapeutics (ARCT.US)$ in game 👀✈️

Moomoo AI

Feb 6 12:49

The recent improvement in total shareholder return could indicate that the business is getting better over time. However, there are 2 warning signs that investors should be aware of. The sentiment around the company seems to be positive lately.

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Delivers Shareholders Incredible 48% CAGR Over 5 Years, Surging 7.2% in the Last Week Alone

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

ARCT Arcturus Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target